<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="736">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959607</url>
  </required_header>
  <id_info>
    <org_study_id>ZRHR-PK-02-JP</org_study_id>
    <secondary_id>ZRHR-PK-02-JP</secondary_id>
    <nct_id>NCT01959607</nct_id>
  </id_info>
  <brief_title>Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of THS 2.2 Following Single Use in Healthy Smokers Compared to Conventional Cigarettes and Nicotine Gum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of the study is to evaluate the pharmacokinetic (PK) profile (rate and the
      amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK
      profiles from a single use of a conventional cigarette (CC) and from a single use of
      nicotine gum in a Japanese population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Ratio of the Maximum Concentration (Cmax) of Nicotine Following Single Use of THS 2.2 and CC (Group 1)</measure>
    <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on the primary outcome, only the ratio THS 2.2:CC is presented.
The ratio THS 2.2:CC of Cmax takes into consideration the blood measurements taken at both Day 1 (THS 2.2) and Day 3 (CC) for the sequence &quot;THS 2.2 then CC&quot;, and Day 1 (CC) and Day 3 (THS 2.2) for the sequence &quot;CC then THS 2.2&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of the Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of THS 2.2 and CC (Group 1)</measure>
    <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on the primary outcome, only the ratio THS 2.2:CC is presented.
The ratio THS 2.2:CC of AUC(0-last) takes into consideration the blood measurements taken at both Day 1 (THS 2.2) and Day 3 (CC) for the sequence &quot;THS 2.2 then CC&quot;, and Day 1 (CC) and Day 3 (THS 2.2) for the sequence &quot;CC then THS 2.2&quot;.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>THS 2.2 then CC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of THS 2.2)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of CC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC then THS 2.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CC)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of THS 2.2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THS 2.2 then NRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of THS 2.2)
Day 2 = wash-out
Day 3 = 2nd intervention (single administration of NRT gum [Nicorette ® 2mg]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRT then THS 2.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single administration of NRT gum [Nicorette ® 2mg])
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of THS 2.2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>THS 2.2</intervention_name>
    <description>Single use of the Tobacco Heating System 2.2 (THS 2.2)</description>
    <arm_group_label>THS 2.2 then CC</arm_group_label>
    <arm_group_label>CC then THS 2.2</arm_group_label>
    <arm_group_label>THS 2.2 then NRT</arm_group_label>
    <arm_group_label>NRT then THS 2.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CC</intervention_name>
    <description>Single use of subject's own conventional cigarette (CC)</description>
    <arm_group_label>THS 2.2 then CC</arm_group_label>
    <arm_group_label>CC then THS 2.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NRT Gum</intervention_name>
    <description>Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette ® 2mg)</description>
    <arm_group_label>THS 2.2 then NRT</arm_group_label>
    <arm_group_label>NRT then THS 2.2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is Japanese.

          -  Smoking, healthy subject as judged by the Investigator.

          -  Subject smokes at least 10 commercially available CCs per day (no brand restrictions)
             for the last 4 weeks.

          -  Subject does not plan to quit smoking in the next 3 months.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  Subject has received medication within 14 days or within 5 half-lives of a drug
             (whichever is longer) which has an impact on CYP2A6 activity.

          -  Female subject is pregnant or breast feeding.

          -  Female subject does not agree to use an acceptable method of effective contraception.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masayuki Sugimoto, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Koganeibashi Sakura Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Koganeibashi Sakura Clinic, 2-11-25, Sakuracho, Koganei-shi</name>
      <address>
        <city>Tokyo</city>
        <zip>184-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 29, 2015</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <firstreceived_results_date>April 24, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Nicotine absorption</keyword>
  <keyword>Modified risk tobacco product</keyword>
  <keyword>Conventional cigarettes</keyword>
  <keyword>Nicotine Replacement Therapy gum (NRT gum)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated (first subject screened): 31 July 2013
At admission (Day -1), all the subjects performed a product trial (Tobacco Sticks and subsequently NRT gum).
From enrollment, they were asked to remain abstinent from smoking for at least 24 hours (Day 0) before being randomized on Day 1 into 1 of the 4 sequences.</recruitment_details>
      <pre_assignment_details>Enrolled population = 65 subjects: 3 subjects exposed to THS 2.2 and NRT gum at Admission but not randomized and 62 randomized as described below:
Sequence &quot;THS 2.2 then CC&quot;: 22 subjects
Sequence &quot;CC then THS 2.2&quot;: 22 subjects
Sequence &quot;THS 2.2 then NRT&quot;: 9 subjects
Sequence &quot;NRT then THS 2.2&quot;: 9 subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>THS 2.2 Then CC</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of THS 2.2)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of CC).</description>
        </group>
        <group group_id="P2">
          <title>CC Then THS 2.2</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of CC)
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of THS 2.2).</description>
        </group>
        <group group_id="P3">
          <title>THS 2.2 Then NRT</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single product use of THS 2.2)
Day 2 = wash-out
Day 3 = 2nd intervention (single administration of NRT gum [Nicorette ® 2mg]).</description>
        </group>
        <group group_id="P4">
          <title>NRT Then THS 2.2</title>
          <description>Each subject will follow the below study design:
Day 0 = Wash-out (1 day)
Day 1 = 1st intervention (single administration of NRT gum [Nicorette ® 2mg])
Day 2 = wash-out
Day 3 = 2nd intervention (single product use of THS 2.2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Washout Period of 1 Day (Day 0)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 1 Day (Day 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Day 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>PK population: all randomized subjects who completed at least 1 of the single-use days, with at least 1 derived PK parameter. Subjects with major protocol deviations impacting the evaluation of the results were excluded.
62 randomized subjects: 44 in Group 1, 18 in Group 2.
60 completers: 42 in Group 1 (2 withdrawn subjects), 18 in Group 2.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then NRT&quot;
Sequence &quot;NRT then THS 2.2&quot;</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Between 23 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33.2" spread="8.61"/>
                <measurement group_id="B2" value="35.8" spread="10.44"/>
                <measurement group_id="B3" value="34.0" spread="9.18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>International Organization for Standardization (ISO) nicotine level</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>≤ 0.6 mg</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt; 0.6 to ≤ 1 mg</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratio of the Maximum Concentration (Cmax) of Nicotine Following Single Use of THS 2.2 and CC (Group 1)</title>
        <description>Based on the primary outcome, only the ratio THS 2.2:CC is presented.
The ratio THS 2.2:CC of Cmax takes into consideration the blood measurements taken at both Day 1 (THS 2.2) and Day 3 (CC) for the sequence &quot;THS 2.2 then CC&quot;, and Day 1 (CC) and Day 3 (THS 2.2) for the sequence &quot;CC then THS 2.2&quot;.</description>
        <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The primary outcome was analyzed using Group 1.
Group 1 consisted of 42 subjects: 21 subjects in the sequence &quot;THS 2.2 then CC&quot; and 21 subjects in the sequence &quot;CC then THS 2.2&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Ratio THS 2.2:CC</title>
            <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ratio of the Maximum Concentration (Cmax) of Nicotine Following Single Use of THS 2.2 and CC (Group 1)</title>
            <description>Based on the primary outcome, only the ratio THS 2.2:CC is presented.
The ratio THS 2.2:CC of Cmax takes into consideration the blood measurements taken at both Day 1 (THS 2.2) and Day 3 (CC) for the sequence &quot;THS 2.2 then CC&quot;, and Day 1 (CC) and Day 3 (THS 2.2) for the sequence &quot;CC then THS 2.2&quot;.</description>
            <units>percentage of [ng/mL]</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103.5" lower_limit="84.9" upper_limit="126.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of the Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of THS 2.2 and CC (Group 1)</title>
        <description>Based on the primary outcome, only the ratio THS 2.2:CC is presented.
The ratio THS 2.2:CC of AUC(0-last) takes into consideration the blood measurements taken at both Day 1 (THS 2.2) and Day 3 (CC) for the sequence &quot;THS 2.2 then CC&quot;, and Day 1 (CC) and Day 3 (THS 2.2) for the sequence &quot;CC then THS 2.2&quot;.</description>
        <time_frame>Derived from multiple blood sampling on Day 1 and Day 3 (1 blood sampling pre-product use and multiple blood sampling over 24 hours post-product use)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The primary outcome was analyzed using Group 1.
Group 1 consisted of 42 subjects: 21 subjects in the sequence &quot;THS 2.2 then CC&quot; and 21 subjects in the sequence &quot;CC then THS 2.2&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Ratio THS 2.2:CC</title>
            <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ratio of the Area Under the Plasma Concentration Versus Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of THS 2.2 and CC (Group 1)</title>
            <description>Based on the primary outcome, only the ratio THS 2.2:CC is presented.
The ratio THS 2.2:CC of AUC(0-last) takes into consideration the blood measurements taken at both Day 1 (THS 2.2) and Day 3 (CC) for the sequence &quot;THS 2.2 then CC&quot;, and Day 1 (CC) and Day 3 (THS 2.2) for the sequence &quot;CC then THS 2.2&quot;.</description>
            <units>percentage of [ng*h/mL]</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96.3" lower_limit="85.1" upper_limit="109.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From ICF signature until the end of the safety follow-up period (7 days after discharge of the subject)</time_frame>
      <desc>The safety was assessed in the safety population, consisting of 65 subjects: 62 randomized subjects (44 in Group 1, 18 in Group 2) and 3 subjects exposed to THS 2.2 and NRT gum from the product trials on Day -1 but not randomized.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then CC&quot;
Sequence &quot;CC then THS 2.2&quot;</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>This population comprises the following sequences:
Sequence &quot;THS 2.2 then NRT&quot;
Sequence &quot;NRT then THS 2.2&quot;</description>
        </group>
        <group group_id="E3">
          <title>Enrolled But Not Randomized</title>
          <description>Subjects who tried the THS 2.2 at Admission (Day -1) but were not randomized in 1 of the 2 groups as they were back-up subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tobacco withdrawal symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO’s prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belongs to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle HAZIZA</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 (58) 242 2625</phone>
      <email>Christelle.Haziza@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
